vs
Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and FLOWSERVE CORP (FLS). Click either name above to swap in a different company.
FLOWSERVE CORP is the larger business by last-quarter revenue ($1.1B vs $722.5M, roughly 1.5× Amneal Pharmaceuticals, Inc.). Amneal Pharmaceuticals, Inc. runs the higher net margin — 10.8% vs 7.6%, a 3.1% gap on every dollar of revenue. On growth, Amneal Pharmaceuticals, Inc. posted the faster year-over-year revenue change (3.9% vs -6.7%). Over the past eight quarters, Amneal Pharmaceuticals, Inc.'s revenue compounded faster (1.5% CAGR vs -3.9%).
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
The Flowserve Corporation is an American multinational corporation and one of the largest suppliers of industrial and environmental machinery such as pumps, valves, end face mechanical seals, automation, and services to the power, oil, gas, chemical and other industries. Headquartered in Irving, Texas, which is in the Dallas–Fort Worth Metroplex, Flowserve employs close to 16,000 employees in more than 50 countries. Flowserve sells products and offers aftermarket services to engineering and c...
AMRX vs FLS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $722.5M | $1.1B |
| Net Profit | $78.0M | $81.7M |
| Gross Margin | 44.3% | 35.6% |
| Operating Margin | 19.6% | 11.2% |
| Net Margin | 10.8% | 7.6% |
| Revenue YoY | 3.9% | -6.7% |
| Net Profit YoY | 410.5% | 10.5% |
| EPS (diluted) | $0.19 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $722.5M | $1.1B | ||
| Q4 25 | $814.3M | $1.2B | ||
| Q3 25 | $784.5M | $1.2B | ||
| Q2 25 | $724.5M | $1.2B | ||
| Q1 25 | $695.4M | $1.1B | ||
| Q4 24 | $730.5M | $1.2B | ||
| Q3 24 | $702.5M | $1.1B | ||
| Q2 24 | $701.8M | $1.2B |
| Q1 26 | $78.0M | $81.7M | ||
| Q4 25 | $35.1M | $-29.0M | ||
| Q3 25 | $2.4M | $219.6M | ||
| Q2 25 | $22.4M | $81.8M | ||
| Q1 25 | $12.2M | $73.9M | ||
| Q4 24 | $-31.1M | $77.5M | ||
| Q3 24 | $-156.0K | $58.4M | ||
| Q2 24 | $6.0M | $72.6M |
| Q1 26 | 44.3% | 35.6% | ||
| Q4 25 | 36.5% | 34.8% | ||
| Q3 25 | 34.9% | 32.4% | ||
| Q2 25 | 39.5% | 34.2% | ||
| Q1 25 | 36.8% | 32.3% | ||
| Q4 24 | 36.0% | 31.5% | ||
| Q3 24 | 38.4% | 31.5% | ||
| Q2 24 | 35.6% | 31.6% |
| Q1 26 | 19.6% | 11.2% | ||
| Q4 25 | 13.8% | 3.5% | ||
| Q3 25 | 9.0% | 6.7% | ||
| Q2 25 | 15.4% | 12.3% | ||
| Q1 25 | 14.4% | 11.5% | ||
| Q4 24 | 10.4% | 10.6% | ||
| Q3 24 | 12.6% | 9.1% | ||
| Q2 24 | 13.6% | 10.5% |
| Q1 26 | 10.8% | 7.6% | ||
| Q4 25 | 4.3% | -2.4% | ||
| Q3 25 | 0.3% | 18.7% | ||
| Q2 25 | 3.1% | 6.9% | ||
| Q1 25 | 1.8% | 6.5% | ||
| Q4 24 | -4.3% | 6.6% | ||
| Q3 24 | -0.0% | 5.2% | ||
| Q2 24 | 0.9% | 6.3% |
| Q1 26 | $0.19 | — | ||
| Q4 25 | $0.10 | $-0.21 | ||
| Q3 25 | $0.01 | $1.67 | ||
| Q2 25 | $0.07 | $0.62 | ||
| Q1 25 | $0.04 | $0.56 | ||
| Q4 24 | $-0.10 | $0.59 | ||
| Q3 24 | $0.00 | $0.44 | ||
| Q2 24 | $0.02 | $0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $197.7M | $792.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $2.3B |
| Total Assets | $3.5B | $5.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $197.7M | $792.4M | ||
| Q4 25 | $282.0M | $760.2M | ||
| Q3 25 | $201.2M | — | ||
| Q2 25 | $71.5M | — | ||
| Q1 25 | $59.2M | — | ||
| Q4 24 | $110.6M | $675.4M | ||
| Q3 24 | $74.0M | — | ||
| Q2 24 | $43.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | $1.6B | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | $1.5B | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — |
| Q1 26 | — | $2.3B | ||
| Q4 25 | $-70.8M | $2.2B | ||
| Q3 25 | $-109.5M | $2.3B | ||
| Q2 25 | $-112.1M | $2.2B | ||
| Q1 25 | $-131.7M | $2.1B | ||
| Q4 24 | $-109.3M | $2.0B | ||
| Q3 24 | $-93.4M | $2.1B | ||
| Q2 24 | $-57.5M | $2.0B |
| Q1 26 | $3.5B | $5.7B | ||
| Q4 25 | $3.7B | $5.7B | ||
| Q3 25 | $3.6B | $5.8B | ||
| Q2 25 | $3.4B | $5.7B | ||
| Q1 25 | $3.4B | $5.5B | ||
| Q4 24 | $3.5B | $5.5B | ||
| Q3 24 | $3.5B | $5.3B | ||
| Q2 24 | $3.5B | $5.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.72× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
